Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Without a provider review, these contraindications may not be identified before treatment begins
The company has seven additional Phase III trials expected to complete in 2026: Obstructive sleep apnea (TRIUMPH-3) Type 2 diabetes (TRIUMPH-1, TRIUMPH-2) Chronic low back pain Metabolic dysfunction-associated steatotic liver disease (MASLD) Cardiovascular and renal outcomes This breadth, more than any single efficacy signal, is what elevates retatrutide from a promising drug to a potential platform
Key Insight : Spend on drug treatment within obesity episodes is over 6 times what it was 3 years ago
No refrigeration required
US$ 29.17
US$ 26.26
US$ 23.65
US$ 26.07
US$ 27.98
:max_bytes(150000):strip_icc()/Health-GettyImages-2190382211-1cdb5299c31943bd92857173e09da74e.jpg)
